TABLE 2

Demographic and clinical characteristics of study cystic fibrosis patients

Patient	Sex	Age years	Atopy^#	Steroid use^¶	FEV₁ %	Genotype	Vitamin D supplementation units·day⁻¹	Under exacerbation⁺	Pathogens^§	ABPA history
1	M	8.2	No	Inhaled	101	F508del/R347P	800	No	none	No
2	M	3.8	No	No	108	F508del/F508del	800	No	S. aureus, S. pneumoniae, H. influenzae	No
3	F	4.7	No	No	ND	F508del/2347delG	1500	Yes	P. aeruginosa, S. pneumoniae, Penicillium spp	No
4	F	11	Yes	No	67	G542X/2708del13	800	No	S. aureus, A. fumigatus	Yes
5	M	8.7	Yes	Inhaled	106	F508del/F508del	800	No	S. aureus	No
6	M	2.6	No	Inhaled	ND	F508del/F508del	800	No	P. aeruginosa, Penicillium spp.	No
7	F	9.1	Yes	No	81	F508del/F508del	1800	No	S. aureus	Yes
8	M	1.1	No	No	ND	F508del/F508del	400	No	S. aureus, H. influenzae, M. catarrhalis	No
9	F	15	Yes	Systemic	38	F508del/F508del	1600	No	P. aeruginosa, S. aureus	Yes
10	M	6.2	No	No	127	F508del/F508del	1200	No	None	No
11	M	10.9	No	No	62	No mutation found	None	No	None	No
12	M	3.1	No	No	ND	F508del/F508del	1000	Yes	S. aureus, H. influenzae	No
13	F	4.8	No	Nasal	139	F508del/F508del	1600	No	S. aureus, H. influenzae	No
14	F	2.6	No	No	ND	F508del/F508del	1800	No	P. aeruginosa, S. aureus, H. influenzae	No
15	M	3.0	No	No	ND	F508del/F508del	1200	No	S. aureus, H. influenzae	No
16	M	4.5	No	No	ND	F508del/F508del	800	No	S. aureus, H. influenzae, Penicillium spp	No
17	F	4.5	No	No	ND	F508del/F508del	800	No	S. aureus	No

M: male; F: female. FEV₁: forced expiratory volume in 1 s; ABPA: Allergic bronchopulmonary aspergillosis; ND: not determined; S. aureus: Staphylococcus aureus; H. influenzae: Haemophilus influenzae; S. pneumoniae: Streptococcus pneumoniae; P. aeruginosa: Pseudomonas aeruginosa; A. fumigatus: Aspergillus fumigatus; M. catarrhalis: Moraxella catarrhalis. ^#: defined as positive history of hay fever, eczema or asthma. ^¶: defined as any treatment with systemic, inhaled or nasal steroids within the past 3 months; ⁺: as defined by [20]; ^§: present in bronchoalveolar lavage fluid at time of brushing.